VEEV:NYE-Veeva Systems Inc. Class A (USD)

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 200.91

Change

+1.82 (+0.91)%

Market Cap

USD 6.08B

Volume

0.85M

Analyst Target

USD 304.05
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veeva Systems Inc is a provider of industry-specific, cloud-based software solutions for the life sciences industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.87 (+1.34%)

USD 11.73B
DOCS Doximity Inc

-0.23 (-0.93%)

USD 4.83B
EVH Evolent Health Inc

+0.37 (+1.36%)

USD 3.36B
TDOC Teladoc Inc

+0.09 (+0.70%)

USD 2.20B
AGTI Agiliti Inc

N/A

USD 1.37B
PHR Phreesia Inc

-0.08 (-0.35%)

USD 1.16B
MPLN MultiPlan Corporation

-0.02 (-2.46%)

USD 0.43B
AMWL American Well Corp

-0.01 (-2.18%)

USD 0.17B
OWLT Owlet Inc

-0.35 (-7.87%)

USD 0.03B
FOXO FOXO Technologies Inc.

N/A

USD 3.00M

ETFs Containing VEEV

CURE:XETRA VanEck Genomics and Healt.. 7.66 % 0.00 %

+0.10 (+0%)

USD 6.89M
EKG First Trust Nasdaq Lux Di.. 7.30 % 0.00 %

+0.07 (+0%)

USD 2.33M
FDHT:XETRA Fidelity Digital Health U.. 5.44 % 0.00 %

+0.03 (+0%)

USD 4.79M
FDHT 4.33 % 0.00 %

N/A

N/A
MOAT:SW VanEck Morningstar US Sus.. 2.72 % 0.00 %

+0.53 (+0%)

N/A
MOAT:AU VanEck Morningstar Wide M.. 2.66 % 0.00 %

+1.00 (+0%)

USD 0.93B
MHOT:AU VanEck Morningstar Wide M.. 2.66 % 0.00 %

+2.29 (+0%)

N/A
MOGB:LSE VanEck Morningstar US Sus.. 2.52 % 0.00 %

+0.58 (+0%)

USD 0.53B
MOAT:LSE VanEck Morningstar US Sus.. 2.51 % 0.00 %

+0.59 (+0%)

USD 0.48B
GOAT:AU VanEck Morningstar World .. 2.30 % 0.00 %

+0.19 (+0%)

USD 0.04B
VVGM:XETRA VanEck Morningstar Global.. 2.17 % 0.00 %

+0.19 (+0%)

USD 0.07B
SMOT 1.46 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 1.24 % 0.00 %

N/A

USD 0.02B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.20 % 0.00 %

+4.85 (+0%)

USD 0.02B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.54 (+0%)

USD 0.82B
MOAT 0.00 % 0.49 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
EASI 0.00 % 0.75 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.06 (+0%)

USD 0.02B
GMVM:XETRA VanEck Morningstar US Sus.. 0.00 % 0.00 %

+0.32 (+0%)

USD 0.53B
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.01 (+0%)

USD 0.02B
CLDL Direxion Daily Cloud Comp.. 0.00 % 0.00 %

N/A

USD 4.57M
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

+0.20 (+0%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.36% 91% A- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.36% 91% A- 62% D
Trailing 12 Months  
Capital Gain 12.19% 100% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.19% 100% F 58% F
Trailing 5 Years  
Capital Gain 44.29% 50% F 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.29% 50% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 14.41% 73% C 79% B-
Dividend Return 14.41% 73% C 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.02% 73% C 24% F
Risk Adjusted Return 34.29% 91% A- 57% F
Market Capitalization 6.08B 100% F 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 109.90 50% 10%
Price/Book Ratio 7.18 17% 12%
Price / Cash Flow Ratio 35.12 17% 7%
Price/Free Cash Flow Ratio 63.60 8% 2%
Management Effectiveness  
Return on Equity 12.58% 92% 66%
Return on Invested Capital 8.78% 75% 59%
Return on Assets 5.01% 83% 72%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.